New research indicates that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a leading health publication demonstrates that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications must be aware of the potential of quick rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to original mass within about one and a half years.
Analyzing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
The team point out that people who shed pounds through dieting typically experience a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Experts believe the mode of action of the injections is key to understanding the amplified regain.
The injections copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Issue?
The NHS advise the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, due to the significant potential of relapse, the therapy is often ongoing.
This view is echoed by pharmaceutical companies, who state that the results "emphasize the long-term character of obesity," akin to managing diseases like diabetes.
User Experiences
Individuals who have come off the medication explain a powerful return of hunger.
"I experienced something flipping and I was suddenly extremely hungry," said a patient.
This challenge is exacerbated if individuals have not adopted lasting lifestyle or habit modifications during therapy.
Growing Use
Recent estimates show that millions of people in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is more common among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while these medications are powerful tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on combined behavioural management.
